Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.67 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.57 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15279997 | 0.88 | PTGDR2 (0.74) | PTGDR2TBXA2RPTGDRCYP2C9CYP3A4 | |
| SCHEMBL1770878 | 0.86 | PTGDR2 (0.66) | PTGDR2TBXA2RPTGDRCYP2C9CYP3A4 | |
| SCHEMBL3048599 | 0.85 | PTGDR2 (0.67) | PTGDR2TBXA2RPTGDRCYP2C9CYP3A4 | |
| SCHEMBL15280015 | 0.81 | PTGDR2 (0.70) | PTGDR2TBXA2RPTGDRCYP2C9 | |
| SCHEMBL3065519 | 0.81 | PTGDR2 (0.55) | PTGDR2TBXA2RPTGDRCYP2C9 | |
| SCHEMBL3048470 | 0.80 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRCYP2C9CYP3A4 | |
| SCHEMBL15280003 | 0.80 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRCYP2C9CYP3A4 | |
| SCHEMBL15280008 | 0.79 | PTGDR2 (0.58) | PTGDR2TBXA2R | |
| SCHEMBL22225179 | 0.79 | PTGDR2 (0.58) | PTGDR2TBXA2R | |
| SCHEMBL22225428 | 0.73 | PTGDR2 (0.73) | PTGDR2TBXA2RPTGDRCYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772312-B2 | Heterocyclic compounds as CRTH2 receptor antagonists | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2014-07-08 | — | — | US | claimed |
| US-20100222270-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | CHEMETEK, LLC | 2010-09-02 | — | — | US | claimed |
| EP-2197438-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | Chemietek, Llc (US) | 2010-06-23 | — | — | EP | claimed |
| WO-2009049021-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | CHEMIETEK, LLC (US) | 2009-04-16 | — | — | WO | claimed |
| EP-2197438-B1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUAN (CN) | 2015-07-15 | — | — | EP | disclosed |
| US-8772312-B2 | Heterocyclic compounds as CRTH2 receptor antagonists | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2014-07-08 | — | — | US | disclosed |
| US-20100222270-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | CHEMETEK, LLC | 2010-09-02 | — | — | US | disclosed |
| EP-2197438-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | Chemietek, Llc (US) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009049021-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | CHEMIETEK, LLC (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222270-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | HRH2, NR3C2, HRH1 | PTGDR2 52/4885TBXA2R 12/4885PTGDR 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.